BRCA in breast cancer: ESMO clinical practice guidelines

Annals of Oncology

Volumn 22, Issue SUPPL. 6, 2011, Pages

  Balmana J ^a   Diez O ^b,c   Rubio, I T ^b   Cardoso, F ^d,e  

^a Medical Oncology Department   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d EUROPEAN SCHOOL OF ONCOLOGY   (Italy)

^e Champalimaud Cancer Center   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ARTICLE; BREAST CANCER; BREAST RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; GENE FREQUENCY; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY; HUMAN; MASTECTOMY; MUTATIONAL ANALYSIS; ONCOGENE; PENETRANCE; POPULATION GENETICS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; SALPINGOOOPHORECTOMY; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC TESTING; HETEROZYGOTE DETECTION; HUMANS;

EID: 80052695765     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr373     Document Type: Article

References (27)

1. Fackental JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007; 7: 937-948.
2. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.
3. Pharoah PD, Antoniou A, Easton D, Ponder B. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008; 358: 2796-2803.
4. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72: 1117-1130.
5. Walsh T, Casadei S, Coats KH et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006; 295: 1379-1388.
6. Kwon JS, Gutierrez-Barrera AM, Young D et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 2010; 28: 4214-4220.
7. Turnbull C, Rahman N. Genetic Predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 2008; 9: 321-345.
8. Hartmann LC, Sellers TA, Schaid DJ et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93: 1633-1637.
9. Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer riskin BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 2004; 22: 1055-1062.
10. Meijers-heijboer H, van Geel B, van Putten WL et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA 1 or BRCA 2 mutation. N Engl J Med 2001; 345: 159-164.
11. Singletary SE, Robb GL. Oncologic safety of skin-sparing mastectomy. Ann Surg Oncol 2003; 10: 95-97.
12. Domchek SM, Friebel TM, Singer CF et al. Association of risk reducing surgery in BRCA1 or BCRA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304: 967-975.
13. Pierce LJ, Phillips KA, Griffith KA et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010; 121: 389-398.
14. Kriege M, Brekelmans CT, Boetes C et al. Efficacy of MRI and mammography for breast cancer screening in women with familial or genetic predisposition. N Engl J Med 2004; 351: 427-437.
15. Gronwald J, Tung N, FoulkesWD et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006; 118: 2281-2284.
16. Gerber B, Krause A, Dieterich M et al. The oncologic safety of skin sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction: an extended follow-up study. Ann Surg 2009; 249: 461-468.
17. Boughey JC, Khakpour N, Meric-Bernstam F et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer 2006; 107: 1440-1447.
18. Pierce LJ, Levin AM, Rebbeck TR et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006; 24: 2437-2443.
19. Andrieu N, Goldgar D, Easton D et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 carrier cohort study (IBCCS). J Natl Cancer Inst 2006; 98: 535-544.
20. Domcheck SM, Friebel TM, Neuhausen SL et al. Mortality after bilateral salpingooophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006; 7: 223-229.
21. Kauff N, Domcheck SM, Friebel TM et al. Risk reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynaecologic cancer: a multicenter, prospective study. J Clin Oncol 2008; 26: 1331-1337.
22. Domcheck SM, Weber BL. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 2006; 25: 5825-5831.
23. Robson M, Offit K. Management of an inherited predisposition to breast cancer. N Engl J Med 2007; 357: 154-162.
24. Drew Y, Calvert H. The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann N Y Acad Sci 2008; 1138: 136-145.
25. Kriege M, Seynaeve C, Meijers-Heijboer H. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009; 27: 3764-3771.
26. Byrski T, Gronwald J, Huzarski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 375-379.
27. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251.